Parexel launches RTSM mobile app

By Melissa Fassbender contact

- Last updated on GMT

Parexel launches RTSM mobile app
Parexel has launched a mobile application for its ClinPhone® randomization and trial supply management (RTSM) service.

According to the company, the application​ is designed to enhance the clinical trial supply management processes, increase patient safety, and improve the chain of custody record for clinical supplies.

The app features built-in barcode scanning capabilities and manages tasks such as confirming correct treatment allocation, dispensing to patients, and processing of medicinal product returns.

The fourth generation of the service was announced​ in May 2015 at which time the company's corporate VP of eClinical Operations, Kevin Bishop, told us the randomization algorithms available within ClinPhone are designed to "ensure that cohorts and treatment allocations are appropriately balanced according to the statistical objective of the study protocol, and that, if required, the blind is maintained.​"

Earlier this month, Parexel also announced​ its plan to acquire The Medical Affairs Company (TMAC). Through the acquisition, the company gains new medical affairs outsourcing capabilities that it said will strengthen and expand its commercialization and market access offerings.

(Feature image: iStock/Poike)

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers